Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Lilly reports OASIS-2 data with mirikizumab in moderate to severe plaque psoriasis

July 17, 2020

Arcutis begins phase IIb portion of phase I/IIb study of ARQ-252 for chronic hand eczema

July 14, 2020

Kymera and Sanofi partner on IRAK4 protein degraders in inflammation and immunology

July 10, 2020

InMed begins second phase I trial of INM-755 for epidermolysis bullosa

July 8, 2020

Cabaletta opens enrollment in phase I study of DSG3-CAART in mucosal-dominant pemphigus vulgaris

July 7, 2020

New phase II trial evaluates CBP-201 for moderate to severe atopic dermatitis

July 6, 2020

Akeso begins first-in-human study of AK-120 for atopic dermatitis

July 2, 2020

Amniox begins first phase III trial of TTAX-01 in diabetic foot ulcers

July 1, 2020

Ilumya approved in Japan for plaque psoriasis

July 1, 2020

FDA approves IND for SFA-002 study in psoriasis

July 1, 2020

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.